Researcher
Hans Wildiers
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Member
From1 Oct 2005 → Today
Projects
1 - 10 of 27
- Breast cancer projectFrom1 Jan 2024 → TodayFunding: Other federal public and semi-governmental institutions
- Real-time qPCR platform enhancing research activities within the Laboratory of Experimental Oncology and the Laboratory of Experimental RadiotherapyFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Building a large blood biobank of patients with new breast cancer diagnosis for future researchFrom1 Jan 2022 → 5 Jun 2023Funding: Other federal public and semi-governmental institutions
- UPTIDER (UZ/KU Leuven Program for post-mortem Tissue Donation to Enhance Research), a unique setting to unravel treatment resistance and disease progression in patients with breast cancer.From1 Oct 2021 → TodayFunding: BOF - projects
- The impact of coaching on quality of life of older cancer patientsFrom27 Sep 2021 → 31 Aug 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Streamlined Geriatric and Oncological evaluation based on IC Technology for holistic patient-oriented healthcare management for older multimorbid patientsFrom1 Apr 2021 → TodayFunding: H2020 - Health, demographic change and wellbeing
- Mechanisms involved in metastasis of luminal breast cancerFrom1 Mar 2021 → 28 Feb 2022Funding: Foundations, funds and other with scientific goal
- The MBC biobank collection.From1 Dec 2020 → 31 Oct 2021Funding: Other federal public and semi-governmental institutions
- Risk prediction and modeling of cancer therapy related cardiotoxicityFrom1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Novel biomarkers in the risk stratification, surveillance and treatment of young breast cancer patients and germline carriers of pathogenic variants in TP53.From1 Sep 2020 → 13 Feb 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
11 - 20 of 474
- Navigating next-generation HR+ /HER2− metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression(2023)
Authors: Patrick Neven, Sileny Han, Yannick Van Herck, Hans Wildiers
- Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer(2023)
Authors: Yentl Lambrechts, Abhishek Garg, Beppe Floris, Patrick Neven, Ines Nevelsteen, François Richard, Annouschka Laenen, Christine Desmedt, Hans Wildiers, Sigrid Hatse
Pages: 270 - 279 - Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab(2023)
Authors: Hans Wildiers
- Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer(2023)
Authors: Yentl Lambrechts, Abhishek Garg, Patrick Neven, Ines Nevelsteen, François Richard, Christine Desmedt, Hans Wildiers, Sigrid Hatse
Pages: 270 - 279 - Neratinib plus fulvestrant plus trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial(2023)
Authors: Hans Wildiers
Pages: 885 - 898 - Innovative translational research approaches for unmet clinical needs in breast cancer(2023)
Authors: Tatjana Geukens, Christine Desmedt, Hans Wildiers, Beppe Floris
- Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer(2023)
Authors: Karen Van Baelen, Ha Linh Nguyen, François Richard, Maxim De Schepper, Tatjana Geukens, Sileny Han, Thaïs Baert, Hans Wildiers, Ann Smeets, Ines Nevelsteen, et al.
- Challenges of caring for older patients with multimorbidity including cancer(2023)
Authors: Hans Wildiers
- Differences in the Tumor Molecular and Microenvironmental Landscape between Early (Non-Metastatic) and De Novo Metastatic Primary Luminal Breast Tumors(2023)
Authors: Yentl Lambrechts, Sigrid Hatse, François Richard, Bram Boeckx, Beppe Floris, Christine Desmedt, Patrick Neven, Diether Lambrechts, Hans Wildiers
- A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry(2023)
Authors: Thaïs Baert, Diether Lambrechts, Ann Smeets, Hans Wildiers